BlueRock Therapeutics

Biotechnology

BlueRock Therapeutics (acquired by Bayer) develops cell therapies derived from induced pluripotent stem cells (iPSCs) for cardiovascular disease, neurology, and immunology. The company's platform can generate unlimited quantities of therapeutic cells from a master cell bank. BlueRock represents the commercial application of iPSC technology.

The Biology of Business

Sign up to be notified when the book is available to order.

Notify Me